Plain-English translation of NCT06805552 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are studying how sarcopenia—a condition involving loss of muscle mass—affects survival in patients with hepatocellular carcinoma (liver cancer) who are being treated with systemic therapy, typically using medications called tyrosine kinase inhibitors (TKIs). By collecting information from about 270 patients over 12 months, the team aims to create a prediction model that can help doctors better understand which patients may be at higher risk and plan their care accordingly.
Liver cancer is serious, and doctors need better tools to predict which patients will do well with treatment and which may need extra support or different approaches. This study is designed to fill that gap by identifying how muscle loss and other health factors influence treatment outcomes.
You likely qualify if…
You likely don't qualify if…
As a participant, you would be followed for 12 months starting from when you begin your systemic therapy medication. The study involves providing access to your medical records, imaging scans (particularly CT scans), and health information to help researchers assess muscle loss and other factors that might affect your outcome. You would not necessarily need extra hospital visits beyond your normal cancer treatment appointments.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
Italy
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Collaborators
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Enrollment target
~270 participants
Started
October 2022
Primary completion
November 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in February 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Dr. Maurizio Biselli Principal Investigator, MD
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.